Hexachlorophene for the Treatment of ALS and Related Disorders
- Technology Benefits
- Endogenous TDP-43 accumulation is decreasedOverexpressed TDP-43 accumulation is decreasedTreatment option for ALS
- Technology Application
- therapeutic agent for ALS
- Detailed Technology Description
- Accumulation of TDP-43 protein is a major causative agent for the pathogenesis of ALS and other neurodegenerative diseases. So far, there is no cure or treatment for diseases related to TDP-43.To identify drug candidates that are capable of targeting TDP-43, two different cell based TDP-43 models were used: cells expressing endogenous TDP-43 protein and cells overexpressing wild-type human TDP-43. Hexachlorophene showed a dramatic reduction in both endogenous as well as overexpressed TDP-43 levels. Hexachlorophene could therefore serve as a potential therapeutic agent for the treatment of ALS and other related disorders.
- *Abstract
-
The University of South Florida has discovered a potential therapeutic agent for amyotrophic lateral sclerosis (ALS) and other related disorders using the compound hexachlorophene.
- Country/Region
- USA
For more information, please click Here
